Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 27, 2019

View Archived Issues

Novel transgenic mouse model of memory impairment

Primary results show improvements in clinical outcomes in TOURMALINE-AL1 phase III study

'Love hormone' plays role in bones, fat

DNA circles drive neuroblastomas

Phase III study begins for first-line treatment of NSCLC with TAK-788

First functional oocytes derived from granulosa cells

Amgen identifies new KRAS G12C inhibitors

New eIF-2-alpha kinase GCN2 inhibitors discovered at RAPT Therapeutics

Idorsia Pharmaceuticals patents lysophosphatidic acid receptor 1 antagonists

Corcept Therapeutics presents glucocorticoid receptor antagonists

RAN protein is ALS target

RBM17 splicing factor maintains leukemia stem cell function in acute myeloid leukemia

Patient enrollment ongoing in phase I study of PF-06940434

Juventas Cell Therapy presents phase I data for CNCT-19 in acute lymphoblastic leukemia

RALA as a novel therapeutic target in triple-negative breast cancer

Pfizer initiates phase I study of PF-07062119

Agios Pharmaceuticals starts recruitment in phase III study of AG-881

Dosing of inarigivir stopped in phase II CATALYST program

Promising overall response and duration of response in phase IIa trial of PTX-200 in breast cancer

Roche and Genentech patent describes YAP1/TEAD interaction inhibitors

Baergic Bio enters agreements with AstraZeneca and Cincinnati Children's Hospital for AZD-7325

Clinical hold on PR-001 study in neuronopathic Gaucher's disease removed

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...